Abstract
Limited data exist on the costs of care of patients with multiple sclerosis (MS) in low- to middle-income nations. The purpose of this study was to describe the economic burden associated with care of Mexican patients with relapsing-remitting MS in a representative sample of the largest institution of the Mexican public healthcare system. We analysed individual data of 492 patients (67 % women) with relapsing-remitting MS registered from January 2009 to February 2011 at the Mexican Social Security Institute. Direct costs were measured about the use of diagnostic tests, disease-modifying therapies (DMTs), symptoms control, medical consultations, relapses, intensive care and rehabilitation. Four groups were defined according to DMT alternatives: (1) interferon beta (IFNβ)-1a, 6 million units (MU); (2) IFNβ-1a, 12MU; (3) IFNβ-1b, 8MU; and (4) glatiramer acetate. All patients received DMTs for at least 1 year. The most frequently used DMT was glatiramer acetate (45.5 %), followed by IFNβ-1a 12MU (22.6 %), IFNβ-1b 8MU (20.7 %), and IFNβ-1a 6MU (11.2 %). The mean cost of a specialised medical consultation was €74.90 (US $107.00). A single relapse had a mean total cost of €2,505.97 (US $3,579.96). No differences were found in annualised relapse rates and costs of relapses according to DMT. However, a significant difference was observed in total annual costs according to treatment groups (glatiramer acetate being the most expensive), mainly due to differences in unitary costs of alternatives. From the public institutional perspective, when equipotent DMTs are used in patients with comparable characteristics, the costs of DMTs largely determine the total expenses associated with care of patients with relapsing-remitting MS in a middle-income country.
Similar content being viewed by others
References
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302
Filippi M, Rocca MA (2011) The role of magnetic resonance imaging in the study of multiple sclerosis: diagnosis, prognosis and understanding disease pathophysiology. Acta Neurol Belg 111:89–98
Kobelt G, Berg J, Atherly D, Hadjimichael O (2006) Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 66:1696–1702
Henriksson F, Fredrikson S, Masterman T, Jönsson B (2001) Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol 8:27–35
Etgen T, Adler-Hunklinger U, Hemmer B (2012) Cognitive impairment as unusual first manifestation in late-onset relapsing-remitting multiple sclerosis. Acta Neurol Belg 112:307–309
Reese JP, John A, Wienemann G, Wellek A, Sommer N, Tackenberg B et al (2011) Economic burden in a German cohort of patients with multiple sclerosis. Eur Neurol 66:311–321
Fattore G, Lang M, Pugliatti M (2012) Treatment experience, burden, and unmet needs (TRIBUNE) study—measuring the socioeconomic consequences of Multiple Sclerosis. Mult Scler 18:5–6
Velázquez-Quintana M, Macías-Islas MA, Rivera-Olmos V, Lozano-Zárate J (2003) Multiple sclerosis in Mexico: a multicentre study. Rev Neurol 36:1019–1022
Pugliatti M, Sotgiu S, Rosati G (2002) The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 104:182–191
Lana-Peixoto MA, Frota ER, Campos GB, Monteiro LP, Brazilian Committee for Treatment and Research in Multiple Sclerosis (2012) The prevalence of multiple sclerosis in Belo Horizonte, Brazil. Arq Neuropsiquiatr 70:102–107
Risco J, Maldonado H, Luna L, Osada J, Ruiz P, Juarez A et al (2011) Latitudinal prevalence gradient of multiple sclerosis in Latin America. Mult Scler 17:1055–1059
Romero M, Arango C, Alvis N, Suarez JC, Duque A (2011) The cost of treatment of multiple sclerosis in Colombia. Value Health 14:S48–S50
Noyes K, Bajorska A, Chappel A, Schwid SR, Mehta LR, Weinstock-Guttman B et al (2011) Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study. Neurology 77:355–363
Sánchez-de la Rosa R, Sabater E, Casado MA, Arroyo R (2012) Cost-effectiveness analysis of disease modifying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients. J Med Econ 15:424–433
Sánchez-De la Rosa R, Sabater E, Casado MA (2011) Budget impact analysis of the first-line treatment of relapsing remitting multiple sclerosis in Spain. Rev Neurol 53:129–138
Manouchehrinia A, Constantinescu CS (2012) Cost-effectiveness of disease-modifying therapies in multiple sclerosis. Curr Neurol Neurosci Rep 12:592–600
Carrá A, Macías-Islas MÁ, Gabbai AA, Correale J, Bolaña C, Sotelo ED et al (2011) Optimizing outcomes in multiple sclerosis: consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America. Ther Adv Neurol Disord 4:349–360
Casado V, Martínez-Yélamos S, Martínez-Yélamos A, Carmona O, Alonso L, Romero L et al (2006) Direct and indirect costs of Multiple Sclerosis in Baix Llobregat (Catalonia, Spain), according to disability. BMC Health Serv Res 6:143
Schoenen J, Gianni F, Schretlen L, Sobocki P (2006) Cost estimates of brain disorders in Belgium. Acta Neurol Belg 106:208–214
Oleen-Burkey M, Castelli-Haley J, Lage MJ, Johnson KP (2012) Burden of a multiple sclerosis relapse: the patient’s perspective. Patient 5:57–69
Triantafyllou N, Triantafillou A, Tsivgoulis G (2009) Validity and reliability of the Greek version of the multiple sclerosis international quality-of-life questionnaire. J Clin Neurol 5:173–177
Zwibel HL, Smrtka J (2011) Improving quality of life in multiple sclerosis: an unmet need. Am J Manag Care 17:S139–145
Hawton A, Green C, Telford CJ, Wright DE, Zajicek JP (2012) The use of multiple sclerosis condition-specific measures to inform health policy decision-making: mapping from the MSWS-12 to the EQ-5D. Mult Scler 18:853–861
Agashivala N, Kim E (2012) Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis. Clin Ther 34:1583–1590
Acknowledgments
This study received financial support by Novartis, Mexico. The company was involved in study design and analysis, but had no role in the selection of patients, data capture, assignations of costs or resources use, the final approval of this article or the decision for submission to publication.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Macías-Islas, M.A., Soria-Cedillo, I.F., Velazquez-Quintana, M. et al. Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis. Acta Neurol Belg 113, 415–420 (2013). https://doi.org/10.1007/s13760-013-0200-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13760-013-0200-z